Daiichi Sankyo signs a $300m deal with Alteogen to develop a subcutaneous version of anti-HER2 cancer drug Enhertu.

Daiichi Sankyo and MSD teased the results of HERTHENA-Lung02 last September and are due to present the full data at the ASCO congress, which gets underway in Chicago tomorrow.